Predilife
“Predict to prevent”
History & vision
2004
Predilife founded
by Stéphane Ragusa
2007
Contract with INSERM (French public research organisation) to access their data cohorts
2013
Contract with BCSC (British Columbia Securities Commission) to access their database on 1,000,000 American women.
2017
First FDA approval for DenSeeMammo
Riviera study (NCT02997384) promoted by Gustave Roussy and financed by ARC seeking to show the acceptability and feasibility of breast cancer risk consultations in doctors’ surgeries.
2018
Predilife becomes a listed company CE marking for MammoRisk and DenSeeMammo
2019
Launch of the MyPeBS study
Commercial launch in Europe and the United States
2020
8 sales representatives
in France and Abroad
Predilife develops predictive tests for medicine of the future: Predictive, Preventive, Personalised and Participatory (4Ps) Predictive medicine consists in anticipating an individual’s future to act in time with customised prevention, either by reducing the risks (known as primary prevention), or by identifying the illness earlier (secondary prevention). Better prevention may be possible for serious pathologies, in particular cancers and infarctus.
Predilife Management, together with 8 collaborators and 8 sales representatives in France and Abroad comprises:
Stéphane Ragusa, Predilife’s CEO. Former École Polytechnique student, he is also a graduate (in Statistics) of the Paris school of Economics, Statistics and Finance (Ensae) and a doctor of biology. He developed this theme of risk prediction in an academic environment on cohorts from INSERM before creating Predilife in 2004. Then he developed the company after training at HEC Challenges+ .
After training as an engineer, Pierre Verdet joined McKinsey before coming site manager (Buc and Budapest) for General Electric. At Predilife, Pierre Verdet is the managing director, in charge of commercial development and the operational implementation of the solution.
Chemical engineer Valerie Helin did her thesis in biology at the Paris-Saclay University in the Gustave Roussy laboratories. In 2007, she directed economic development at Cancer Campus and began working for Predilife as the academic collaborations manager. In 2016, she became a full member of the Predilife team as the scientific and medical affairs manager.
With a Master’s degree in bioinformatics and biostatistics from Paris-Sud University, Emilien Gauthier is also software engineer and has a doctorate in data-mining medical risk scores from Telecom Bretagne. He joined Predilife in 2007 and is currently the technical and R&D manager.
Partner in the European MyPEBS study, in charge of the breast cancer risk evaluation platform.
The randomised MyPeBS (My Personal Breast Screening) study aims to compare current organised screening – based on the sole criterion of age (except in the case of women identified as very high risk) – with a new screening strategy proposing a type and frequency of examinations based on each woman’s risk level.
The study, financed by the European Union and promoted by Unicancer, plans to recruit 85,000 women aged between 40 and 70 in 6 countries (France, United Kingdom, Italy, Belgium, Israel, Spain) for a period of 4 years. Half the women will follow standard screening and for the other half, screening will be based on assessment of their risk.
Predilife is one of the partners in the MyPeBS study in charge of the individual breast cancer risk evaluation platform. For more information: www.mypebs.eu
This project has received European Union funding under the research and innovation programme Horizon 2020 – grant agreement no. 755394.
